GLP1R in Parkinson's Disease

NCT03659682 on ClinicalTrials.gov · last registry update 2018-09-06

120 participants. Its estimated completion date, 31 December 2024, has passed with no update to the record. Primary outcome, as filed: Motor Function. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Oslo University Hospital
Sponsor type: Other
Enrollment: 120
Started: 2019-01-02
Primary completion: 2024-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Motor Function

Conditions studied

Parkinson Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.